Endometriosis Trial: Study of NBI-56418 in Endometriosis
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group
study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in
a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at
the end of Week 12, follow-up continued every 4 weeks for 12 weeks.